News

Noxxon Pharma, developing medicines based on its proprietary Spiegelmer technology, has achieved an important milestone in its drug discovery and development partnership with Eli Lilly and Company. Noxxon’s

Santarus has reported that its collaboration partner, Cosmo Technologies (Cosmo), a subsidiary of Cosmo Pharmaceuticals has completed enrollment of 514 patients in the European Phase III clinical trial

Shire has recalled five lots and voluntary market withdrawal of one lot of the attention-deficit/hyperactivity disorder (ADHD) patch Daytrana. Shire is taking this action because some Daytrana patches

Vetter has added new 24,000-square-foot facility at the Illinois Science + Technology Park in Skokie, which is expected to enable life-sciences firms to streamline their early development process

University of Leeds has a new laboratory, which will focus on making small scale process development more greener, cheaper and effective. The laboratory was built with an investment

Mocon is introducing film cells as optional add-ons to its recently launched OpTech – O2 Platinum analyzer. The additional capability sets the performance bar higher for the unit

Schreiner MediPharm’s transparent-Hologram-Seal is set to provide evidence against tampering and counterfeiting of drugs. The hologram has been helpful in ensuring packaged pharmaceutical safety of drugs. Reportedly, the

Addex Pharmaceuticals has extended its research collaboration with Merck & Co, through an affiliate, for an additional year. The collaboration is focused on developing positive allosteric modulators (PAM)

Dyax has received FDA approval to market Kalbitor, indicated for the treatment of hereditary angioedema in patients 16 years and above. Angioedema is the rapid swelling of the